LysoCAT
Cationic lysolipids
A proprietary family of cationic lysolipids designed to form LNPs/lipoplexes with oligonucleotide cargo and support cellular uptake and transfection.
NATx
Nucleic-Acid Therapeutics
Expanding the therapeutic potential of nucleic acids through chemistry, delivery and conjugation.
The opportunity
Delivery determines therapeutic potential
Oligonucleotides can address biological targets that are difficult to reach with conventional small molecules.
Their therapeutic application depends on protecting the payload, delivering it to the relevant cells and enabling the intended intracellular activity.
The platform
Complementary approaches to nucleic-acid delivery
NATx brings together 4Ammonium’s capabilities in cationic lipid chemistry, oligonucleotide chemistry and covalent drug conjugation.
PON
Proprietary Oligonucleotide Chemistry
A chemistry platform for preparing and functionalising oligonucleotide-based compounds, including new molecular architectures and prodrug strategies.
Collaboration model
Designed for proprietary and partner programmes
NATx technologies can be developed as proprietary opportunities or explored in combination with an external oligonucleotide programme.
Build
Select the chemistry, carrier or conjugation strategy that fits the payload.
Evaluate
Investigate assembly, delivery and cellular performance in an appropriate experimental model.
Develop
Define a validation or co-development route around the resulting opportunity.
Partnering
Explore a NATx collaboration
Contact us to discuss an oligonucleotide payload, delivery challenge or conjugation opportunity.
Discuss NATx with us